Publications (132) View all
-
Article: Therapy-Related Myeloid Neoplasms in 39 Korean Patients: A Single Institution Experience.
Hee Jae Huh, Soo Hyun Lee, Keon Hee Yoo, Ki Woong Sung, Hong Hoe Koo, Kihyun Kim, Jun-Ho Jang, Chulwon Jung, Sun-Hee Kim, Hee-Jin Kim[show abstract] [hide abstract]
ABSTRACT: Therapy-related myeloid neoplasms (t-MN) occur as late complications of cytotoxic therapy. This study reviewed clinical and cytogenetic characteristics of patients with t-MN at a single institution in Korea. The study subjects included 39 consecutive patients diagnosed with t-MN. Each subject's clinical history of previous diseases, treatments, and laboratory data was reviewed, including cytogenetics. The primary diagnosis was hematologic malignancy in 14 patients and solid tumor in 25 patients. Therapy-related acute myeloid leukemia (t-AML, 66.7%) was found to be more common than therapy-related myelodysplastic syndrome (t-MDS). Primary hematologic malignancies that were commonly implicated included mature B-cell neoplasm and acute leukemia. Breast cancer was the most common primary solid tumor. The mean time interval from cytotoxic therapy initiation to t-MN detection was 49 months. Chromosomal aberrations were observed in 35 patients, and loss of chromosome 5, 7, or both accounted for 41% of all cases. Balanced rearrangements occurred in 13 patients; these patients showed shorter latency intervals (mean, 38 months) than patients with loss of chromosome 5 or 7 (mean, 61 months). In this study, we determined the clinical and cytogenetic characteristics of Korean patients with t-MN. Although our results were generally consistent with those of previous reports, we found that t-MN resulting from de novo leukemia was common and that t-AML was more common than t-MDS at presentation. Multi-institutional studies involving a larger number of patients and additional parameters are required to investigate the epidemiology, genetic predisposition, and survival rate of t-MN in Korea.Annals of laboratory medicine. 03/2013; 33(2):97-104. -
Article: Chronic lymphocytic leukemia in Korean patients: frequent atypical immunophenotype and relatively aggressive clinical behavior.
[show abstract] [hide abstract]
ABSTRACT: Chronic lymphocytic leukemia (CLL) is a mature B-cell neoplasm characterized by the expansion of CD5-positive lymphocytes in peripheral blood. While CLL is the most common type of leukemia in Western populations, the disease is rare in Asians. Hence, clinical and laboratory data and studies of CLL in Asian populations have been limited. In this study, we investigated the clinical and laboratory characteristics of CLL in Korea. A total of 39 patients who had been diagnosed with CLL during the period from January 2000 to October 2010 at a single institution in Korea were examined. Clinically, 67 % of the patients were classified as having advanced Binet stages B or C. Up to 56 % of the patients had an atypical immunophenotype with high frequencies of FMC7 positivity and strong CD22 positivity. Twenty-six patients (67 %) received chemotherapy, and more than half of the treated patients (54 %) expired. The overall survival rate at 5 years was estimated at 71 %, which was lower than previously reported. These findings suggested that CLL in Korea has atypical immunophenotypes and that its clinical behavior may be more aggressive than that in Western populations.International journal of hematology 02/2013; · 1.17 Impact Factor -
Article: Inclusion of hemoglobin level in prognostic score provides better prognostic stratification in patients with acute promyelocytic leukemia (APL).
Silvia Park, Su Jin Lee, Kihyun Kim, Jun Ho Jang, Dong Hwan Kim, Kyu Hyung Lee, Je Hwan Lee, Jung Hee Lee, Dae Young Kim, Dae-Young Jang, Hawk Kim, Jae Hoo Park, Hun Mo Ryoo, Sung Hwa Bae, Min Kyung Kim, Myung Soo Hyun, Young Don Joo, Won Sik Lee, Sang Min Lee, Chul Won Jung[show abstract] [hide abstract]
ABSTRACT: The clinical outcomes of acute promyelocytic leukemia (APL) have improved greatly, but treatment failure still occurs. Identification of patients with poor prognosis is fundamental, and we propose a new clinical prognostic system (CBC-score) consisting of WBC, platelet count, and hemoglobin level. Between 1995 and 2009, 156 patients with APL from seven institutes in Korea were retrospectively reviewed. In the new CBC-score system, each of the following (WBC ≥10 × 109/L, platelet <40 × 109/L, hemoglobin <8.0 g/dL) was considered as a risk factor; the sum of each was designated as the CBC-score. With a median follow-up of 8.4 years, the complete remission (CR) rate was 81.4 % (127/156), while 24 (15.4 %) were considered as treatment failures due to early death (ED). The 5-year overall survival (OS), leukemia-free survival, and cumulative incidence of relapse were 73.8, 82.8, and 13.5 %, respectively. Compared to the individual CBC parameters, combined prognostic systems such as PETHEMA or CBC-score provided better prognostic stratification. Compared to PETHEMA stratification, the proposed prognostic CBC-score system showed better stratification of APL patients in terms of CR rates (p = 0.004), OS (p = 0.004), and ED (p = 0.008). This retrospective study suggests that the proposed CBC-score may provide better prognostic stratification of APL patients.International journal of hematology 02/2013; · 1.17 Impact Factor -
Article: Gene mutation profiles and prognostic implications in Korean patients with T-lymphoblastic leukemia.
Hee Jae Huh, Soo Hyun Lee, Keon Hee Yoo, Ki Woong Sung, Hong Hoe Koo, Jun Ho Jang, Kihyun Kim, Seok Jin Kim, Won Seog Kim, Chul Won Jung, Ki-O Lee, Sun-Hee Kim, Hee-Jin Kim[show abstract] [hide abstract]
ABSTRACT: Genetic alterations implicated in the leukemogenesis of T cell acute lymphoblastic leukemia (T-ALL) have been identified in recent years. In this study, we investigated gene mutation profiles and prognostic implications in a series of Korean T-ALL patients. The study patients were 29 Korean patients with T-ALL; 13 adults (45 %) and 16 children (55 %; male-to-female ratio, 25:4). Clinical, hematologic, and cytogenetic findings were reviewed. We performed mutation analyses for NOTCH1, FBXW7, PHF6, and IL7R genes and survival analyses according to the mutational status. Gene mutations were identified in 66 % of the patients in our series (19/29). Eighteen patients (62 %) had NOTCH1/FBXW7 mutations. Sixteen patients (55 %) had NOTCH1 mutations including nine novel mutations, and eight patients (28 %) had known FBXW7 mutations. Eight patients (28 %; six males and two females) had PHF6 mutations including four novel mutations. Three patients (10 %) had IL7R mutations, which were all novel in-frame insertion or deletion-insertions. The gene mutation profile combined with cytogenetics and FISH study for the p16 gene detected genetic aberrations in 90 % of patients (26/29). There was no significant difference in the frequency of gene mutations between the pediatric and adult patients with T-ALL. Survival analyses suggested a favorable prognostic implication of NOTCH1 mutations in adult T-ALL. Gene mutation studies for NOTCH1, FBXW7, PHF6, and IL7R could detect genetic alterations in a majority of Korean T-ALL patients with novel mutations. We observed similar mutation profiles between adult and pediatric T-ALL, and a favorable prognostic implication of NOTCH1 mutations in adult T-ALL.Annals of Hematology 01/2013; · 2.62 Impact Factor -
SourceAvailable from: Jae Hoon Lee
Dataset: MM(BBMT김혁)
Shin Kim, Jae Hoon Lee, Cheolwon Suh, Sang Kyun Sohn, Kihyun Kim, Hawk Kim, Soo-Mee Bang, Hee-Jung Sohn, Je-Jung Lee, Dong-Hwan Kim